These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 14348839)

  • 1. [Antibody formation and cancer growth].
    SEELICH F
    Wien Klin Wochenschr; 1954 Sep; 66(35-36):635-8. PubMed ID: 14348839
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modification of nonspecific for tumor antigens in homotransplantation].
    AVDEEV GI
    Biull Eksp Biol Med; 1955 Mar; 39(3):62-5. PubMed ID: 14378271
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
    Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
    J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
    Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
    Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells.
    Siva AC; Kirkland RE; Lin B; Maruyama T; McWhirter J; Yantiri-Wernimont F; Bowdish KS; Xin H
    J Immunol Methods; 2008 Jan; 330(1-2):109-19. PubMed ID: 18096183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor antibodies in ovarian cancer.
    Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
    Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
    Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
    Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
    J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Contemporary molecular-biological methods of cancer diagnosis and monitoring based on the humoral immune response to tumor-associated antigens].
    Shebzukhov IuV; Belousov PV; Khlgatian SV; Sazykin AIu; Kuprash DV; Nedospasov SA
    Mol Gen Mikrobiol Virusol; 2007; (2):3-6. PubMed ID: 17600920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
    García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
    Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis.
    Zhang JY
    Cancer Detect Prev; 2004; 28(2):114-8. PubMed ID: 15068835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humoral response to selected antigens of Yersinia enterocolitica and Yersinia pseudotuberculosis in the course of yersiniosis in humans. I. Occurrence of antibodies to Yersinia lipopolisacharydes and Yop proteins by ELISA].
    Rastawicki W
    Med Dosw Mikrobiol; 2006; 58(4):303-19. PubMed ID: 17642308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone.
    Marvin JS; Zhu Z
    Curr Opin Drug Discov Devel; 2006 Mar; 9(2):184-93. PubMed ID: 16566289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal and bispecific antibodies as novel therapeutics.
    Booy EP; Johar D; Maddika S; Pirzada H; Sahib MM; Gehrke I; Loewen S; Louis SF; Kadkhoda K; Mowat M; Los M
    Arch Immunol Ther Exp (Warsz); 2006; 54(2):85-101. PubMed ID: 16648969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-based identification of cell surface antigens: targets for cancer therapy.
    Loo DT; Mather JP
    Curr Opin Pharmacol; 2008 Oct; 8(5):627-31. PubMed ID: 18804182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
    Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Shijubo Y; Abe S; Hirohashi Y; Torigoe T; Sato N; Watanabe N
    Lung Cancer; 2005 May; 48(2):217-21. PubMed ID: 15829321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody formation and nutrition. II. Antibody titre in lambs and goats fed on homologous and heterologous milk using influenza and diphtheria vaccine as antigens.
    OBERG G; MELLANDER O
    Acta Soc Med Ups; 1955 Apr; 60(1-2):14-6. PubMed ID: 14387806
    [No Abstract]   [Full Text] [Related]  

  • 19. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
    Mizukami M; Hanagiri T; Yasuda M; Kuroda K; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; So T; Ichiki Y; Sugaya M; So T; Takenoyama M; Sugio K; Yasumoto K
    Cancer Res; 2007 Sep; 67(17):8351-7. PubMed ID: 17804751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
    Kocak E; Lute K; Chang X; May KF; Exten KR; Zhang H; Abdessalam SF; Lehman AM; Jarjoura D; Zheng P; Liu Y
    Cancer Res; 2006 Jul; 66(14):7276-84. PubMed ID: 16849577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.